Karger Publishers –
125 Years of Experience
in Medical and
Scientific Publishing

Karger Publishers – independent, family-run
and Swiss-based.

It is our goal to serve the global scientific community
with innovative and outstanding publications in
all fields of medical science. This means dedication to
maintaining the highest standards of quality, as well
as personalized service for authors, editors and readers.

www.karger.com

Please order a free copy of the Karger Festschrift
‘Connecting the World of Biomedical Science’
by sending your address to 125years@karger.com.
Aims and Scope
The rapidly expanding area of research known as neuroimmunomodulation, which has shown how the nervous and immune system interacts with the immune system via neural, hormonal, and paracrine actions. This area of basic and clinical research, Neuroimmunomodulation, reports on all aspects of these interactions. Basic investigations consider all neural and humoral interactions between molecular genetics through cell regulation to integrative systems of the body. The journal also aims to clarify the basic mechanisms involved in the pathogenesis of the CNS pathology in AIDS patients and in various neurodegenerative diseases. Although primarily devoted to research articles, timely brief communications are also accepted.

Manuscripts
Manuscripts should be submitted using the online submission website at: www.karger.com/nim

Authors are asked to suggest three to four potential reviewers for their manuscript. These experts on the topic of the article should not be from the same institution as the author(s). The names and the full postal and e-mail addresses of potential reviewers should be submitted with each article. Editors will consider these suggestions but are not bound by them.

Abstracts: Each paper needs an abstract of up to 250 words. Abstracts for Original Papers should be structured with subheadings: Name(s), Objective(s), Methods, Results, Conclusion(s). The words used in the subheadings of the Abstract are not included in the 250 words of the Abstract.

Footnotes: Avoid footnotes if at all possible. When essential, they should be numbered consecutively and typed at the foot of the appropriate page.

Tables and illustrations: Tables (numbered in arabic numerals) should be prepared on separate sheets, and each should have a suitable heading. Manuscripts should be numbered in Arabic numerals and legends for the figures should be submitted on a separate page. For the reproduction of illustrations, only good drawings and black-and-white photographs can be accepted; negatives or photocopies cannot be used. Due to technical reasons, figures with a screen background should not be submitted. When possible, group several illustrations on one block for reproduction (max. size 180 x 223 mm) or provide crop marks. On the back of each illustration, indicate its number, the author's name, and 'top' with a soft pencil. Electronically submitted b/w half-tone and color illustrations must have a final resolution of 300 dpi after scaling, line drawings one of 800–1,200 dpi.

Color illustrations: Online edition: Color illustrations are reproduced free of charge. In the print version, the illustrations are reproduced in black and white. Please avoid referring to the colors in the text and figure legends.

Print edition: Up to 6 color illustrations per page can be integrated within the text at CHF 800.00 per page.

Acknowledgments, including, where relevant, credit to the sources of grant support, should be placed before the references.

References: In the text identify references by Arabic numerals [in square brackets]. Material submitted for publication but not yet accepted should be noted as (unpublished data) and not be included in the reference list. The list of references should include only those publications which are cited in the text. Do not alphabetize, number references in the order in which they are first mentioned in the text. The surnames of all authors followed by 'et al.' should be given. There should be no punctuation other than a comma to separate the authors. Preferably, please cite all authors. Abbreviate journal names according to the Index Medicus system. Also see International Committee of Medical Journal Editors. Uniform requirements for manuscripts submitted to biomedical journals (www.icmje.org).

Examples
(b) Papers published only with DOI numbers: Thorehill JC, Boucher W, Spear K: Serum interleukin-6 reflects disease severity and morbidity in mastocytosis patients. Int Arch Allergy Immunol DOI: 10.1159/000063858.

Supplementary Material
Supplementary material is restricted to additional data that are not necessary for the scientific integrity and conclusions of the paper. Please note that all supplementary files will undergo editorial review and should be submitted together with the original manuscript. The Editors reserve the right to limit the scope and length of the supplementary material. Supplementary material must meet production quality standards for Web publication without the need for any modification or editing. In general, supplementary files should not exceed 10 Mb in size. All figures and tables should have titles and legends and all files should be supplied separately and named clearly. Acceptable files and formats are: Word or PDF files, Excel spreadsheets (only if the data cannot be converted properly to a PDF file), and video files (.mov, .avi, .mpeg).

Reprints
Order forms and a price list are sent with the proofs. Orders placed after the issue is printed are subject to considerably higher rates.

Digital Object Identifier (DOI)
Karger Publishers supports DOIs as unique identifiers for articles. A DOI number will be printed on the title page of each article. DOIs can be useful in the future for identifying and citing articles published online without volume or issue information. More information can be found at www.doi.org.

NIH-Funded Research
The U.S. National Institutes of Health (NIH) mandates under the Public Access Policy that final, peer-reviewed manuscripts appear in its digital database within 12 months of the official publication date. As a service to authors, Karger submits the final version of your article on your behalf to PubMed Central. For those selecting our premium Author's Choice service, we will send your article immediately upon publishing, accelerating the visibility of your work. NIH Public Access Policy is available at http://publicaccess.nih.gov/policy.htm.

Self-Archiving
Karger permits authors to archive their pre-prints (i.e. pre-refereeing) or post-prints (i.e. final draft post-refereeing) on their personal or institution's servers, provided the following conditions are met: Articles may not be used for commercial purposes, must be linked to the publisher's version, and must acknowledge the publisher's copyright. Authors selecting Karger's Author's Choice feature, however, are also permitted to archive the final, published version of their article, which includes copyediting and design improvements as well as citation links.

Electronic Proofs
Unless indicated otherwise, proofs will be e-mailed to the corresponding author.

Reprints
Order forms and a price list are sent with the proofs. Orders placed after the issue is printed are subject to considerably higher rates.

For those selecting our premium Author's Choice service, we will send your article immediately upon publishing, accelerating the visibility of your work. NIH Public Access Policy is available at: http://pub-licaccess.nih.gov/policy.htm.

Author's Choice
Karger's Author's Choice service broadly the reach of your article and gives all users worldwide free and full access for reading, downloading and printing at www.karger.com. The option is available for a one-time fee of CHF 3,000.00, which is a permissible cost in grant allocation. More information can be found at www.karger.com/authors_choice.
The current epidemic of diabetes, obesity and related disorders is a driving force in the development of new technologies. Technological advances offer great new opportunities for the treatment of these chronic diseases. This review presents an update of developments that promise to revolutionize the treatment of diabetes. It examines hospital and outpatient care, intensive insulin therapy, blood glucose monitoring and innovative steps towards the construction of an artificial pancreas.

Providing a comprehensive overview on the latest advances, this volume of Frontiers in Diabetes will be of particular interest to all healthcare providers involved in the daily management of patients with diabetes or related diseases.

Contents

Preface: Grassi, G.

Glycemic Control
• Glucose Control in Diabetes: Targets and Therapy: Bolli, G.B.; Porcellati, F.; Lucidi, P.; Fanelli, C.G.
• Pregnancy and Diabetes: Lapolla, A.; Dalfrà, M.G.
• Management of Hyperglycemia in Hospitalized Patients: Critical Care Setting: Grassi, G.; Bonomo, M.
• Management of Hyperglycemia in Hospitalized Patients: Noncritical Care Setting: Pichardo-Lowden, A.R.

Home Blood Glucose Monitoring
• Self-Monitoring in Diabetes: When and How Much?: Pintaudi, B.; Nicolucci, A.
• Interfering Factors in Quality of Glucose Measurement: Hellman, R.

Continuous Glucose Monitoring
• Continuous Glucose Monitoring: Professional and Real Time: Zisser, H.; Lane, J.E.; Shivers, J.P.
• Real-Time Continuous Glucose Monitoring in Children and Adolescents: Battelino, T.; Dovì, K.; Bratina, N.
• Real-Time Continuous Glucose Monitoring in Adult Outpatients: Bonomo, M.; Grassi, G.; Di Bartolo, P.; Maran, A.

Insulin Delivery System
• Subcutaneous Insulin Pump: Lepore, G.; Tommaselli, L.
• Continuous Subcutaneous Insulin Infusion and Sensor-Augmented Pump Therapy in Children and Adolescents: Rabbone, I.; Frontino, G.; Bonfanti, R.
• Predective Low Glucose Suspend: An Option for Routine Outpatient Care: Danne, T.; Kordonouri, O.; Thomas, A.

Closed-Loop Insulin-Delivery System
• Artificial Pancreas: A Review of Fundamentals and Inpatient and Outpatient Studies: Del Favero, S.; Bruttomesso, D.; Cobelli, C.

Alternatives to Insulin Injection
• Continuous Intraperitoneal Insulin Infusion from Implantable Pumps: Renard, E.

Devices to Support Treatment Decisions
• Devices to Support Treatment Decisions in Type 1 Diabetes: The Diabeo System: Franc, S.; Charpentiers, G.
• Diabetes Interactive Diary: A Mobile Phone-Based Telemedicine System for Carbohydrate Counting and Bolus Calculator: Vespasiani, G.; Rossi, M.C.

Electronic Medical Record
• Standardized Information Exchange in Diabetes: Integrated Registries for Governance, Research, and Clinical Practice: Canicci, F.; Di Iorio, C.T.; Massi Benedetti, M.
• Type 1 Diabetes Care: It’s Not All Technology: Reach, G.

Author Index / Subject Index
Contents

See the journal website for contents
Contents

Introduction

• Special Issue on Glucocorticoid Therapy in Rheumatic Diseases: Cutolo, M.; Chrousos, G.P.; Pincus, T.

Basic Research concerning Glucocorticoids

• Stress, the Stress System and the Role of Glucocorticoids: Nicolaides, N.C.; Kyratzis, E.; Lamprokostapoulou, A.; Chrousos, G.P.; Charmandari, E.
• One Hormone, Two Actions: Anti-and Pro-Inflammatory Effects of Glucocorticoids: Cruz-Topete, D.; Cidlowski, J.A.

Efficacy of Low-Dose Glucocorticoids in Clinical Trials

• Clinical Trials Documenting the Efficacy of Low-Dose Glucocorticoids in Rheumatoid Arthritis: Pincus, T.; Cutolo, M.
• Initial High-Dose Prednisolone Combination Therapy Using COBRA and COBRA-Light in Early Rheumatoid Arthritis: Rasch, L.A.; van Tuyll, L.H.D.; Lems, W.F.; Boers, M.

Safety of Low-Dose Glucocorticoids in Rheumatoid Arthritis

• Safety of Glucocorticoids in Rheumatoid Arthritis: Evidence from Recent Clinical Trials: Santiago, T.; Da Silva, J.A.P.
• Glucocorticoids in Early Rheumatoid Arthritis: Are the Benefits of Joint-Sparing Effects Offset by the Adverse Effect of Osteoporosis? The Clinical Effects on Local and General Bone in the Utrecht Study and the CAMERA-II Study: Jacobs, J.W.G.; Bijlsma, J.W.J.; van Laar, J.M.
• The Safety of Low-Dose Glucocorticoids in Rheumatic Diseases: Results from Observational Studies: Hwang, Y.G.; Saag, K.
• Hypothalamic-Pituitary-Adrenal Axis Function in Patients with Rheumatoid Arthritis Treated with Different Glucocorticoid Approaches: Alten, R.; Wiebe, E.

Observational Studies and Clinical Experience with Low-Dose Glucocorticoids

• The Past versus the Present, 1980–2004: Reduction of Mean Initial Low-Dose, Long-Term Glucocorticoid Therapy in Rheumatoid Arthritis from 10.3 to 3.6 mg/Day, Concomitant with Early Methotrexate, with Long-Term Effectiveness and Safety of Less than 5 mg/Day: Pincus, T.; Sokka, T.; Cutolo, M.
• Oral Low-Dose Glucocorticoids Should be Included in Any Recommendation for the Use of Non-Biologic and Biologic Disease-Modifying Anti-Rheumatic Drugs in the Treatment of Rheumatoid Arthritis: Caporali, R.; Todoerti, M.; Sicre, C.A.; Montecucco, C.; Cutolo, M.
• Glucocorticoids in Juvenile Idiopathic Arthritis: Schiappapietra, B.; Varnier, G.; Rosina, S.; Consolaro, A.; Martini, A.; Ravelli, A.

The easiest way to order: www.karger.com/nim
The recent discovery of kisspeptin, neurokinin B and dynorphin A in a subset of neurons in the hypothalamus which regulate the secretion of gonadotropin-releasing hormone has revolutionized our understanding of the regulation of reproduction in man and animals.

In this Neuroendocrinology special issue four commissioned reviews from leaders in the field describe the latest developments and set the scene for further research and new discoveries.

Contents

Preface

• New Developments in Kisspeptin, Neurokinin B and Dynorphin A Regulation of Gonadotropin-Releasing Hormone: Millar, R.P.

At the Cutting Edge

• The Role of Neurokinin B Signalling in Reproductive Neuroendocrinology: Grachev, P.; Millar, R.P.; O’Byrne, K.T.
• A Role for Neurokinin B in Pulsatile GnRH Secretion in the Ewe: Goodman, R.L.; Coolen, L.M.; Lehman, M.N.
• Neuroanatomy of the Human Hypothalamic Kisspeptin System: Hrabovszky, E.
• Effects and Therapeutic Potentials of Kisspeptin Analogs: Regulation of the Hypothalamic-Pituitary-Gonadal Axis: Matsui, H.; Asami, T.
• Author Index/Subject Index
The *Journal of Innate Immunity* is a bimonthly journal covering all aspects within the area of innate immunity, including evolution of the immune system, molecular biology of cells involved in innate immunity, pattern recognition and signals of 'danger', microbial corruption, host response and inflammation, mucosal immunity, complement and coagulation, sepsis and septic shock, molecular genomics, and development of immunotherapies. The journal publishes original research articles, short communications and reviews.

**Editors-in-Chief**

Heiko Herwald, Lund
Arne Egesten, Lund

Selected contributions

- Mast Cell-Deficient Kit^W^ Mice Develop House Dust Mite-Induced Lung Inflammation despite Impaired Eosinophil Recruitment: de Boer, J.D.; Yang, J.; van den Boogaard, F.E.; Hoogendijk, A.J.; de Beer, R.; van der Zee, J.S.; Roelofs, J.J.T.H.; van’t Veer, C.; de Vos, A.F.; van der Poll, T. (Amsterdam)
- Mycobacterium tuberculosis-Induced Neutrophil Extracellular Traps Activate Human Macrophages: Braian, C.; Hogaia, V.; Stendahl, O. (Linköping)
- Control of Myeloid Cell Trafficking in Resolution: Norling, L.V.; Perretti, M. (London)
- Cystic Fibrosis Transmembrane Conductance Regulator Recruitment to Phagosomes in Neutrophils: Zhou, Y.; Song, K.; Painter, R.G.; Aiken, M. (New Orleans, La); Reiser, J. (Bethesda, Md); Stanton, B.A. (Hanover, N.H)
- Nauseef, W.M. (Coralville, Iowa); Wang, G. (New Orleans, La)

More information at www.karger.com/jin
Original Papers

213 Lipopolysaccharide-Induced Sickness Behavior in Lactating Rats Decreases Ultrasonic Vocalizations and Exacerbates Immune System Activity in Male Offspring
Nascimento, A.F.; Alves, G.J.; Massoco, C.O. (São Paulo); Teodorov, E. (Santo André); Felicio, L.F. (São Paulo); Bernardi, M.M. (São Paulo/Santo André)

222 Lipopolysaccharide-Induced Maternal Inflammation Affects the Gonadotropin-Releasing Hormone Neuron Development in Fetal Mice
Sharova, V.S.; Izvolskaia, M.S.; Zakharova, L.A. (Moscow)

243 Lipopolysaccharide-Stimulated Transglutaminase 2 Expression Enhances Endocytosis Activity in the Mouse Microglial Cell Line BV-2
Kawabe, K.; Takano, K.; Moriyama, M.; Nakamura, Y. (Izumisano)

250 The Association of Openness Personality Trait with Stress-Related Salivary Biomarkers in Burning Mouth Syndrome

256 Role of Adrenocorticotropic Hormone in the Modulation of Pollinosis Induced by Pollen Antigens
Hashimoto, M. (Osaka); Sato, E.F.; Hiramoto, K. (Suzuka); Kasahara, E.; Inoue, M.; Kitagawa, S. (Osaka)

263 Temporal Gene Expression in the Hippocampus and Peripheral Organs to Endotoxin-Induced Systemic Inflammatory Response in Caspase-1-Deficient Mice
Mastronardi, C.A.; Paz-Filho, G. (Canberra, A.C.T.); Zanoni, M. (Verona); Molano-González, N. (Bogotá); Arcos-Burgos, M. (Canberra, A.C.T.); Licinio, J.; Wong, M.-L. (Adelaide, S.A.)

274 Effects of Subcutaneous LPS Injection on Gestational Length and Intrauterine and Neonatal Mortality in Mice
Pujol Lopez, Y.; Steinbusch, H.W.M.; Rutten, B.; Kenis, G. (Maastricht); van den Hove, D.L. (Maastricht/Würzburg); Myint, A.M. (Maastricht/Munich)

Rapid Communication

233 Paracrine Effects of Mesenchymal Stem Cells-Conditioned Medium on Microglial Cytokines Expression and Nitric Oxide Production
Ooi, Y.Y.; Dheen, S.T.; Sam Wah Tay, S. (Singapore)

278 Erratum